Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI. Rangwala F, et al. Among authors: nixon ab. Invest New Drugs. 2014 Aug;32(4):700-9. doi: 10.1007/s10637-014-0089-2. Epub 2014 Apr 9. Invest New Drugs. 2014. PMID: 24711126 Free PMC article. Clinical Trial.
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
Strickler JH, Starodub AN, Jia J, Meadows KL, Nixon AB, Dellinger A, Morse MA, Uronis HE, Marcom PK, Zafar SY, Haley ST, Hurwitz HI. Strickler JH, et al. Among authors: nixon ab. Cancer Chemother Pharmacol. 2012 Aug;70(2):251-8. doi: 10.1007/s00280-012-1911-1. Epub 2012 Jun 29. Cancer Chemother Pharmacol. 2012. PMID: 22744359 Free PMC article. Clinical Trial.
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI. Uronis HE, et al. Among authors: nixon ab. Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13. Oncologist. 2013. PMID: 23485624 Free PMC article. Clinical Trial.
Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon AB, Augustine C, Beasley G, Tyler DS, Osada T, Morse MA, Ling L, Lyerly HK, Blobe GC. Hanks BA, et al. Among authors: nixon ab. J Clin Invest. 2013 Sep;123(9):3925-40. doi: 10.1172/JCI65745. Epub 2013 Aug 8. J Clin Invest. 2013. PMID: 23925295 Free PMC article.
126 results